newsfilter
← Latest News
GlobeNewswire·

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label long-term safety trial expected in